Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550793 | 1.00 | DNM1 (0.46) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL2484241 | 1.00 | DNM1 (0.46) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL15334858 | 1.00 | DNM1 (0.46) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL28968204 | 1.00 | DNM1 (0.46) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL2484947 | 1.00 | DNM1 (0.46) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL1940546 | 0.97 | CES1 (0.42) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL2123995 | 0.90 | CA12 (0.46) | CES2CES1GPR84TSHRALDH1A1 | |
| SCHEMBL303673 | 0.89 | CHRM2 (0.39) | TSHRALDH1A1TDP1 | |
| SCHEMBL9531787 | 0.87 | DNM1 (0.39) | DNM1CES2CES1GPR84PPARG | |
| SCHEMBL11686419 | 0.87 | TSHR (0.45) | DNM1CES2CES1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731249-A1 | A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN | AATEC Medical GmbH (DE) | 2026-04-29 | — | — | EP | claimed |
| US-12584101-B2 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | INFINANT HEALTH, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20250388855-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | Infinant Health, Inc (US) | 2025-12-25 | — | — | US | claimed |
| US-20250127853-A1 | METHODS AND COMPOSITIONS FOR REDUCING NEUTROPHILS OR NEUTROPHIL INFILTRATION AT THE SITE OF DISEASE | GNUBIOTICS SCIENCES SA (CH) | 2025-04-24 | — | — | US | claimed |
| US-20250084140-A1 | COMPOSITIONS FROM GASTROINTESTINAL TRACT MUCINS, AND USES THEREOF | GNUBIOTICS SCIENCES SA (CH) | 2025-03-13 | — | — | US | claimed |
| WO-2024261142-A1 | A RECOMBINANT HUMAN ALPHA-1 ANTITRYPSIN GLYCOPROTEIN | AATEC MEDICAL GMBH (DE) | 2024-12-26 | — | — | WO | claimed |
| CN-119023827-A | Mass spectrum identification method of O-GalNAc glycosylation modified peptide fragment in protein enzymolysis liquid | 中国科学院大连化学物理研究所 | 2024-11-26 | — | — | CN | claimed |
| US-20240385183-A1 | METABOLIC AND MICROBIAL BIOMARKERS FOR DETECTION OF PANCREATICOBILIARY CANCERS | NORTHWESTERN UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-20240382560-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | GNUBIOTICS SCIENCES SA (CH) | 2024-11-21 | — | — | US | claimed |
| US-20240271083-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | INFINANT HEALTH, INC. (US) | 2024-08-15 | — | — | US | claimed |
| US-20230295256-A1 | COMPOSITIONS FROM GASTROINTESTINAL TRACT MUCINS, AND USES THEREOF | GNUBIOTICS SCIENCES SA (CH) | 2023-09-21 | — | — | US | claimed |
| WO-2023041979-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | GNUBIOTICS SCIENCES SA (CH) | 2023-03-23 | — | — | WO | claimed |
| WO-2023037165-A1 | METHODS AND COMPOSITIONS FOR REDUCING NEUTROPHILS OR NEUTROPHIL INFILTRATION AT THE SITE OF DISEASE | GNUBIOTICS SCIENCES SA (CH) | 2023-03-16 | — | — | WO | claimed |
| US-8580857-B2 | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | AU JESSIE L-S (US) | 2013-11-12 | — | — | US | claimed |
| US-20110142794-A1 | Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy | AU JESSIE L-S | 2011-06-16 | — | — | US | claimed |
| EP-1429713-A4 | METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY | AU JESSIE L S (US) | 2007-08-08 | — | — | EP | claimed |
| CN-1589138-A | Methods and compositions for determining chemosensitizing doses of suramin for use in combination therapy | AU JESSIE L-S (US) | 2005-03-02 | — | — | CN | claimed |
| US-20040180955-A1 | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | AU JESSIE L-S (US) | 2004-09-16 | — | — | US | claimed |
| EP-1429713-A2 | METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY | Au, Jessie L.S. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003026574-A2 | METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY | AU JESSIE L-S (US) | 2003-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584101-B2 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | FUT5, VNN1, FUT8 | DNM1 4843/4885CES2 3984/4885CES1 2349/4885 |
| US-20250388855-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | MRPL21, VNN1, NT5M | DNM1 4711/4885CES2 4513/4885CES1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.